Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 11;16(20):3449.
doi: 10.3390/cancers16203449.

What Is the Prognostic Value of the Pathologic Response after Neoadjuvant Radiotherapy in Soft Tissue Sarcoma? An Institutional Study Using the EORTC-STBSG Response Score

Affiliations

What Is the Prognostic Value of the Pathologic Response after Neoadjuvant Radiotherapy in Soft Tissue Sarcoma? An Institutional Study Using the EORTC-STBSG Response Score

Anastasia Stergioula et al. Cancers (Basel). .

Abstract

Background/Objectives: The relationship between pathologic findings in soft tissue sarcoma (STS) after neoadjuvant treatment and oncological outcomes remains uncertain due to varying evaluation methods and cut-off values. This study aims to assess pathologic findings after neoadjuvant radiotherapy in STS using the EORTC-STBSG response score and evaluate its prognostic value. Methods: Clinical and outcome data from 44 patients were reviewed. Resected specimens were re-evaluated to measure viable cells, necrosis, fibrosis, and hyalinization. Local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and overall survival (OS) were analyzed using Kaplan-Meier survival analysis. Cox proportional hazards regression was used for univariate and multivariate analyses to correlate outcomes with pathologic response. Results: The median percentages of viable cells, necrosis, and fibrosis/hyalinization were 20%, 11%, and 40%, respectively. A pathologic complete response (pCR), defined as ≤5% viable cells, was achieved in 25% of cases. Local recurrence occurred in 33% of cases, with a significantly higher rate of 64% after R1 resection compared to 22% after R0 resection. Distant metastases were observed in 42% of patients, primarily in the lungs. The 3-year rates for LRFS, DMFS, and OS were 65%, 54%, and 67%, respectively. A correlation between outcomes and tumor size, grade and histological subtype was observed. Classifying pathologic response by the EORTC-STBSG score failed to show an association with outcomes. Patients achieving pCR showed lower risk of LR and improved OS. Conclusions: While the EORTC-STBSG score did not show a prognostic value, resection specimens with ≤5% viable cells were linked to improved LRFS and OS.

Keywords: EORTC response score; neoadjuvant radiotherapy; pathologic response; preoperative radiotherapy; soft tissue sarcoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Representative figures from the different EORTC–STBSG grades corresponding to the outcome of radiotherapy (eosin–hematoxylin stain, 200× original magnification). (A) collagenous stroma with complete absence of neoplastic cells, (B) only scattered, single viable cells into a necrotic and collagenous stroma, (C) tumor cells interspersed throughout the stroma, occupying less than 10% of the area, (D) tumor cells can be easily identified, with a diffuse growth pattern occupying less than 50% of the area and (E) poor response to radiotherapy showing increased population of viable tumor cells occupying more than 50% of the area.
Figure 2
Figure 2
Kaplan–Meier curves for local recurrence free survival (LRFS), distance metastasis free survival (DMFS) and overall survival (OS) of the studied patient population.

Similar articles

Cited by

References

    1. Hayes A.J., Nixon I.F., Strauss D.C., Seddon B.M., Desai A., Benson C., Judson I.R., Dangoor A. UK Guidelines for the Management of Soft Tissue Sarcomas. Br. J. Cancer. 2024;2010 doi: 10.1038/s41416-024-02674-y. - DOI - PMC - PubMed
    1. Gronchi A., Miah A.B., Dei Tos A.P., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S., et al. Soft Tissue and Visceral Sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2021;32:1348–1365. doi: 10.1016/j.annonc.2021.07.006. - DOI - PubMed
    1. von Mehren M., Kane J.M., Agulnik M., Bui M.M., Carr-Ascher J., Choy E., Connelly M., Dry S., Ganjoo K.N., Gonzalez R.J., et al. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2022;20:815–833. doi: 10.6004/jnccn.2022.0035. - DOI - PMC - PubMed
    1. Haas R.L.M., Delaney T.F., O’Sullivan B., Keus R.B., Le Pechoux C., Olmi P., Poulsen J.P., Seddon B., Wang D. Radiotherapy for Management of Extremity Soft Tissue Sarcomas: Why, When, and Where? Int. J. Radiat. Oncol. Biol. Phys. 2012;84:572–580. doi: 10.1016/j.ijrobp.2012.01.062. - DOI - PubMed
    1. O’Sullivan B., Davis A.M., Turcotte R., Bell R., Catton C., Chabot P., Wunder J., Kandel R., Goddard K., Sadura A., et al. Preoperative versus Postoperative Radiotherapy in Soft-Tissue Sarcoma of the Limbs: A Randomised Trial. Lancet. 2002;359:2235–2241. doi: 10.1016/S0140-6736(02)09292-9. - DOI - PubMed

LinkOut - more resources